Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down1.700 -0.010 (-0.585%)

24/09/2021 10:38

Sihuan Pharm (00460) unit signs agreement with SignalChem

[ET Net News Agency, 24 September 2021] Sihuan Pharmaceutical Holdings Group Ltd.
(00460) said its subsidiary Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) and
SignalChem Lifesciences Corporation (SignalChem) have entered into a collaboration and
licensing agreement for the development and commercialization interests of SLC-391, a
highly potent and highly selective AXL targeting inhibitor, in the Greater China region.
Xuanzhu Biopharm will pay SignalChem an upfront fee of US$13 million. In addition,
SignalChem is entitled to receive milestone payments including development, registration
and commercialization, and royalties in the future. The group will obtain the exclusive
research, development, manufacture and commercialization rights for each indication of
SLC-391 in the field of oncology in the Greater China region. (RC)

Remark: Real time quote last updated: 19/10/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.